Response to Comment on Vistisen et al. A validated prediction model for endstage kidney disease in type 1 diabetes. Diabetes care 2021;44:901–907

Dorte Vistisen; Gregers S. Andersen; Adam Hulman; Stuart J. McGurnaghan; Helen M. Colhoun; Jan E. Henriksen; Reimar W. Thomsen; Frederik Persson; Peter Rossing; Marit E. Jørgensen

doi:10.2337/dci21-0010

Response to Comment on Vistisen et al. A validated prediction model for endstage kidney disease in type 1 diabetes. Diabetes care 2021;44:901–907

Dorte Vistisen^*
, Gregers S. Andersen
, Adam Hulman
, Stuart J. McGurnaghan
, Helen M. Colhoun
, Jan E. Henriksen
, Reimar W. Thomsen
, Frederik Persson
, Peter Rossing
, Marit E. Jørgensen

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › Research › peer-review

Original language	English
Journal	Diabetes Care
Volume	44
Issue number	6
Pages (from-to)	e140-e141
ISSN	0149-5992
DOIs	https://doi.org/10.2337/dci21-0010
Publication status	Published - Jun 2021

Funding

served as a consultant for AstraZeneca, As-tellas, Bayer, Boehringer Ingelheim, Gilead, Merck, Mundipharma, Vifor, Sanofi, and Novo Nordisk A/S (all honoraria to his institution) and received research grants from AstraZeneca and Novo Nordisk A/S. M.E.J. has received research grants from AstraZe-neca, Amgen, Sanofi, and Boehringer Ingel-heim (investigator-initiated research). M.E.J. also owns shares in Novo Nordisk A/S. No other potential conflicts of interest relevant to this article were reported. Funding. The Steno Diabetes Centers (Aarhus and Copenhagen) are partially funded by an unrestricted donation from the Novo Nordisk Foundation. Duality of Interest. D.V. and G.S.A. own shares in Novo Nordisk A/S. F.P. reports having received research grants from AstraZene-ca and lecture fees from AstraZeneca, MSD, Janssen, Eli Lilly, Boehringer Ingelheim, Novo Nordisk A/S, and Novartis as well as being a consultant/advisory board member for Astra-Zeneca, Bayer, Amgen, and MSD. P.R. has

Documents & Links

10.2337/dci21-0010

SDU Link

Check access to the material in SDU Library's search engine

Cite this

Vistisen, D., Andersen, G. S., Hulman, A., McGurnaghan, S. J., Colhoun, H. M., Henriksen, J. E., Thomsen, R. W., Persson, F., Rossing, P., & Jørgensen, M. E. (2021). Response to Comment on Vistisen et al. A validated prediction model for endstage kidney disease in type 1 diabetes. Diabetes care 2021;44:901–907. Diabetes Care, 44(6), e140-e141. https://doi.org/10.2337/dci21-0010

@article{bdc28f144197497d835271b5075ef370,

title = "Response to Comment on Vistisen et al. A validated prediction model for endstage kidney disease in type 1 diabetes. Diabetes care 2021;44:901–907",

author = "Dorte Vistisen and Andersen, \{Gregers S.\} and Adam Hulman and McGurnaghan, \{Stuart J.\} and Colhoun, \{Helen M.\} and Henriksen, \{Jan E.\} and Thomsen, \{Reimar W.\} and Frederik Persson and Peter Rossing and J{\o}rgensen, \{Marit E.\}",

note = "Funding Information: served as a consultant for AstraZeneca, As-tellas, Bayer, Boehringer Ingelheim, Gilead, Merck, Mundipharma, Vifor, Sanofi, and Novo Nordisk A/S (all honoraria to his institution) and received research grants from AstraZeneca and Novo Nordisk A/S. M.E.J. has received research grants from AstraZe-neca, Amgen, Sanofi, and Boehringer Ingel-heim (investigator-initiated research). M.E.J. also owns shares in Novo Nordisk A/S. No other potential conflicts of interest relevant to this article were reported. Funding Information: Funding. The Steno Diabetes Centers (Aarhus and Copenhagen) are partially funded by an unrestricted donation from the Novo Nordisk Foundation. Duality of Interest. D.V. and G.S.A. own shares in Novo Nordisk A/S. F.P. reports having received research grants from AstraZene-ca and lecture fees from AstraZeneca, MSD, Janssen, Eli Lilly, Boehringer Ingelheim, Novo Nordisk A/S, and Novartis as well as being a consultant/advisory board member for Astra-Zeneca, Bayer, Amgen, and MSD. P.R. has",

year = "2021",

month = jun,

doi = "10.2337/dci21-0010",

language = "English",

volume = "44",

pages = "e140--e141",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association Inc.",

number = "6",

}

Vistisen, D, Andersen, GS, Hulman, A, McGurnaghan, SJ, Colhoun, HM, Henriksen, JE, Thomsen, RW, Persson, F, Rossing, P & Jørgensen, ME 2021, 'Response to Comment on Vistisen et al. A validated prediction model for endstage kidney disease in type 1 diabetes. Diabetes care 2021;44:901–907', Diabetes Care, vol. 44, no. 6, pp. e140-e141. https://doi.org/10.2337/dci21-0010

TY - JOUR

T1 - Response to Comment on Vistisen et al. A validated prediction model for endstage kidney disease in type 1 diabetes. Diabetes care 2021;44:901–907

AU - Vistisen, Dorte

AU - Andersen, Gregers S.

AU - Hulman, Adam

AU - McGurnaghan, Stuart J.

AU - Colhoun, Helen M.

AU - Henriksen, Jan E.

AU - Thomsen, Reimar W.

AU - Persson, Frederik

AU - Rossing, Peter

AU - Jørgensen, Marit E.

N1 - Funding Information: served as a consultant for AstraZeneca, As-tellas, Bayer, Boehringer Ingelheim, Gilead, Merck, Mundipharma, Vifor, Sanofi, and Novo Nordisk A/S (all honoraria to his institution) and received research grants from AstraZeneca and Novo Nordisk A/S. M.E.J. has received research grants from AstraZe-neca, Amgen, Sanofi, and Boehringer Ingel-heim (investigator-initiated research). M.E.J. also owns shares in Novo Nordisk A/S. No other potential conflicts of interest relevant to this article were reported. Funding Information: Funding. The Steno Diabetes Centers (Aarhus and Copenhagen) are partially funded by an unrestricted donation from the Novo Nordisk Foundation. Duality of Interest. D.V. and G.S.A. own shares in Novo Nordisk A/S. F.P. reports having received research grants from AstraZene-ca and lecture fees from AstraZeneca, MSD, Janssen, Eli Lilly, Boehringer Ingelheim, Novo Nordisk A/S, and Novartis as well as being a consultant/advisory board member for Astra-Zeneca, Bayer, Amgen, and MSD. P.R. has

PY - 2021/6

Y1 - 2021/6

U2 - 10.2337/dci21-0010

DO - 10.2337/dci21-0010

M3 - Comment/debate

C2 - 34016609

AN - SCOPUS:85114490339

SN - 0149-5992

VL - 44

SP - e140-e141

JO - Diabetes Care

JF - Diabetes Care

IS - 6

ER -